A device for stimulating nerves adjacent the vagina includes a nerve stimulating element coupled to a main body. The nerve stimulating element is positioned and designed to stimulate the vesical, Frankenhauser's and/or inferior hypogastric plexuses. The device may reside in the vaginal fornices. An implant is also provided which has a nerve stimulating element in contact with a uterosacral ligament. The device positioned in the vagina may be used to charge a power source for an implant which may be a capacitor.

Described herein are devices, systems, and methods for wireless power transfer utilizing a midfield source and implant. In one variation, a midfield source may be realized by a patterned metal plate composed of one of more subwavelength structures. These midfield sources may manipulate evanescent fields outside a material (e.g., tissue) to excite and control propagating fields inside the material (e.g., tissue) and thereby generate spatially confined and adaptive energy transport in the material (e.g., tissue). The energy may be received by an implanted device, which may be configured for one or more functions such as stimulation, sensing, or drug delivery.

The invention features a pharmaceutical suspension containing drug particles, a drug delivery device anchored in the mouth for continuously administering the pharmaceutical suspension, and methods of their use.

The present disclosure provides a device (30) for delivering a substance to the inner ear. The device (30) comprises a pressure oscillator (32) configured to generate pressurised air at a predetermined oscillation frequency, an aural probe (31) comprising an air passageway extending from a first end of the aural probe (31) to a second end of the aural probe (31), the first end being the end to be inserted into the ear canal, a tube (33) arranged to couple the second end of the aural probe (31) to the pressure oscillator (32), and a pressure relief valve (34) disposed at the tube (33) and/or the aural probe (31) configured to release a portion or the generated pressurised air from within the tube (33) and/or the aural probe (31) when a pressure within the tube (33) and/or the aural probe (31) reaches a predetermined maximum pressure. The present disclosure further provides a method for delivering a substance to the inner ear, the method comprising the steps of: (i) administering the substance to the middle ear; and (ii) generating oscillating air pressure within the ear canal.

Embodiments herein relate to an implantable device comprising a casing, a semi-permeable membrane plug at or near a first end of the casing, a piston, beads, and an opening for release of the beads from the implantable device within a body of a human or an animal; wherein the implantable device is configured to be implanted within the body of the human or the animal during delivery of the beads into the body of the human or the animal; wherein the beads comprise a core and a shell with the core being enclosed by the shell and the beads contain a drug; and wherein the implantable device is configured to produce a desired flow rate of elution of the drug from the implantable device when the implantable device is implanted within the body of the human or the animal.

Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.

This disclosure features methods and compositions for treating diseases of the gastrointestinal tract with a TLR agonist.

Implantable devices for drug delivery in response to detected biometric parameters associated with an opioid drug overdose and associated systems and methods are disclosed herein. An implantable drug delivery device configured in accordance with some embodiments of the present technology can include a housing and a reservoir configured to contain a drug for treatment of the opioid overdose. The implantable drug delivery device can also include one or more sensors each configured to detect the biometric parameters associated with the overdose. The implantable drug delivery device can further include a controller configured to receive signals related to the biometric parameter, determine whether the overdose occurred based on the signals, and, if the overdose is detected, cause the drug to be delivered to the patient.

An apparatus, including a refillable therapeutic substance delivery device including a reservoir, the reservoir being configured to be located in an adult middle ear cavity of a human recipient, wherein in some instances, the device is configured such that the reservoir is accessible through a tympanic membrane of the recipient.

The present invention relates to a porous structure-based magnetically actuated microrobot and a fabricating method therefor, wherein the porous structure-based magnetically actuated microrobot is based on a natural polymer having biocompatibility and biodegradability, so that the precise targeting of the porous microrobot through the attachment of magnetic nanoparticles and the drug and cell delivery using the porous microrobot can be attained.